{"title": "PDF", "author": "PDF", "url": "https://www.bluecrossma.org/medical-policies/sites/g/files/csphws2091/files/acquiadam-assets/310%20Immunoglobulins%20Policy.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "1 Pharmacy Medical Policy Immunoglobulin s Policy Table of Contents Policy: Commercial Policy History Endnotes Policy: Medicare Information Pertaining to All Policies Forms Coding Information References Policy Number: 310 BCBSA Reference Number: 8.01.05 Related # 422, RSV Immunoprophylaxis (RSV -IVIg) Policy Commercial Members : Managed Care (HMO and POS), PPO, and Indemnity Note: All requests for indications listed and not listed on the medical policy guidelines may be submitted to BCBSMA Pharmacy Operations by completing the Prior Authorization Form on the last page of this document. This medication is covered by the pharmacy benefit. It is also covered under the Home Infusion Therapy benefit. 2 Prior Authorization Information Prior Authorization Step Therapy Quality Care Dosing Pharmacy Operations: Tel: 1 -800-366-7778 Fax: 1 -800-583-6289 Policy last updated 7/1/2023 Pharmacy (Rx) or Medical (MED) benefit coverage Rx MED (MPBT -2) To request for coverage: Physicians may call, fax, or mail the attached form ( Formulary Exception/Prior Author ization form ) to the address below. Blue Cross Blue Shield of Massachusetts Pharmacy Operations Department 25 Technology Place Hingham, MA 02043 Individual Consideration: Policy for requests that do not meet clinical c riteria of this policy, see section labeled Individual Consideration Policy applies to Commercial Members: Managed Care (HMO and POS), PPO and Indemnity MEDEX with Rx plan Managed Major Medical with Custom BCBSMA Formulary Comprehensive Managed Major Medical with Custom BCBSMA Formulary Managed Blue for Seniors with Custom BCBSMA Formulary We may cover intravenous immunoglobulin (IVIg) and subcutaneous IG for the following diagnoses only: Blood disorders Bone marrow transplant patients (for prevention of infection or GVH prevention) Multiple myeloma and immunoproliferative neoplasms Immune neutropenia Multiple myeloma without mention of remission Multiple myeloma in remission Other immunoproliferative neoplasms without mention of remission Other immunoproliferative neoplasms in Agranulocytosis Common variable immunodeficiency, are less than 400mg/dl Idiopathic thrombocytopenic purpura (ITP). Infectious diseases HIV and AIDS Prevention of infection in HIV -infected children and IgG levels are less than 400mg/dl Prior to solid organ transplant, treatment of patients at high risk of antibody -mediated rejection, including highly sensitized patients, and those receiving an ABO incompatible organ Solid organ transplant recipients at risk for cytomegalovirus infections and pneumonia. Severe Anemia associated with human parvovirus B19. Toxic Shock Syndrome 3 Neurologic conditions: Guillain -Barr\u00e9 Syndrome (GBS) Chronic severe myasthenia gravis, for severe exacerbations causing disability Myasthenic crisis /exacerbations (i.e., an acute episode of respiratory muscle weakness) in patients with a contraindication to plasma exchange Severe refractory Myasthenia gravis in patients with chronic debilitating disease despite treatment with cholinesterase inhibitors, or complicati ons from or failure of cortico steroids and/or azathioprine. Hereditary and idiopathic peripheral Sclerosis: for patients with relapsing -remitting disease (not primary or secondary progressive MS) Chronic inflammatory demyelinating polyneuropathy Demyelinating polyneuropathy associated with IgM paraproteinemia patients with GM1 antibodies and block Stiff-Person/M an syndrome Other: Dermatomyositis/polymyositis which is refractory to treatment with corticosteroids in combination with other immunosuppressive agents. Kawasaki syndrome Prior to solid organ transplant; treatment of patients at high risk of antibody -mediated rejection, including highly sensitized patients, and those receiving an ABO incompatible organ , Effective January 2007 Following solid organ transplant; treatment of antibody -mediated rejection . Effective January 2007. Patients wi th neuromyelitis optica as an alternative for patients with contraindication or lack of response to first -line treatment . Patients with severe, progressive autoimmune failed treatment with conventional respond to anticholinesterase medications and/or corticosteroids. Antiphospholipid syndrome Hemolytic disease of the fetus and newborn (aka erythroblastosis fetalis) Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Pediatric Acute -onset Neuropsychiatric Syndrome (PANS) We do not cover intravenous immunoglobulin in the following conditions: Blood disorders Acquired factor VIII inhibitors Acute lymphoblastic leukemia Aplastic anemia Diamond body myositis , because it does not work in this disorder Rheumatoid arthritis and other connective tissue diseases including systemic lupus Scleroderma Other vasculitides e.g., nodosa), Goodpasture's associated with other connective tissue diseases. Neurologic conditions Epilepsy Multiple sclerosis: primary progressive or secondary progressive types, because it has not been shown to offer additional health benefits to patients with these types of MS Paraneoplastic syndromes excluding Eaton -Lambert syndrome . Infectious Chronic sinusitis Recurrent otitis media. Other syndrome Epidermolysis bullosa aquisita Recurrent spontaneous pre gnancy loss Idiopathic environmental illness Myasthenia gravis in patients responsive to immunosuppressive treatment Post-infectious sequelae Organ transplant rejection (not antibody -mediated rejection which is covered) Uveitis Demyelinating optic neuritis Recent onset dilated cardiomyopathy Other disorders not listed above. Medicare HMO BlueSM and Medicare PPO BlueSM Members Coverage Indications, Limitations, and/or Medical Necessity Effective October 1, 2002, IVIg is covered for the treatment of biopsy Bullosa Acquisita for the following patient subpopulations : Patients who have failed conventional therapy. Medicare Administrative Contractors (MACs) have the discretion to define what constitutes failure of conventional therapy; Patients in whom conventional therapy is ot herwise contraindicated. Contractors have the discretion to define what constitutes contraindications to conventional therapy; or 5 Patients with rapidly progressive disease in whom a clinical response could not be affected quickly enough using conventional agents. In such situations IVIg therapy would be given along with conventional treatment(s) and the IVIg would be used only until the conventional therapy could take effect. In addition, IVIg for the treatment of autoimmune mucocutaneous blistering diseases must be used only for short -term therapy and not as a maintenance therapy. Contractors have the discretion to decide what constitutes short -term therapy. National Coverage Determination (NCD) for Intravenous Immune Globulin for the Treatment of Autoimmune Mucocutaneous Blistering Diseases (250.3) Other Information Blue Cross Blue Shield of Massachusetts (BCBSMA*) members (other than Medex\u00ae; Blue MedicareRx, Medicare Advantage plans that include prescription drug coverage) will be required to fill their prescript ions for the above medications at one of the providers in our retail specialty pharmacy network, see link below: Link to Specialty Pharmacy List CPT Codes / HCPCS Codes / ICD Codes Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non -coverage as it applies to an individual member. A draft of future ICD -10 Coding related to this document, as it might look today, is included below for your reference. Providers should report all services u sing the most up -to-date industry -standard procedure, revenue, and diagnosis codes , including modifiers where applic able. The following codes are included below for informational purposes only; this is not an all-inclusive list. The above medical necessity criteria MUST be met for the following codes to be covered for Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity: HCPCS Codes HCPCS codes: Code Description C9072 , 500 mg J0850 Injection, cytomegalovirus immune globulin intravenous vial [Cytogam] J1459 Injection, immune globulin (Privigen), intravenous, nonlyophilized (e.g., liquid), 500 mg J1554 Injection, immune globulin (asceniv), 500 mg J1556 Injection, immune globulin Bivigam , 500 mg J1557 Injection, immune globulin, Gammaplex, intravenous, nonlyophilized (e.g., liquid), 500 mg J1558 Injection, immune globulin Xembify, 100 mg J1559 Injection, immune globulin Hizentra, 100 mg J1561 Injection, Gamunex / Gamunex / Gammaked , nonlyophilized mg J1566 Injection, immune globulin, intravenous, lyophilized (e.g., powder), 500 mg Panglobulin ] J1568 Injection, immune globulin, Octagam, intravenous, nonlyophilized (e.g., liquid), 500 mg 6 J1569 Injection, immune globulin, Gammagard liquid, intravenous, nonlyophilized, (e.g., liquid), mg J1572 Injection, immune globulin, Flebogamma/Flebogamma Dif, intravenous, nonlyophilized (e.g., liquid), 100 mg immunoglobulin J1599 Injection, immune globulin, intravenous, nonlyophilized (e.g., liquid), not otherwise specified, 500 biologics (i.e. Asceniv, Cutaquig , Panzyga ) Other Information Preferred Home Infusion Therapy Network Referring providers are encouraged to use these preferred Home Infusion providers to obtain these medications. Preferred Home Infusion Therapy Provider Contact Information: Accredo Health Group Phone: therapies only, 1 -888-699-7440 Website: www.coramhc.com Individual Consideration All our medical policies are written for the majority of people with a given condition. Each policy is based on medical science. For many of our medical policies, each individual's unique clinical circumstances may be considered in light of current scientific literature. Physicians may send relevant clinical information for individual patients for consideration to: Blue Cross Blue Shield of Massachusetts Pharmacy Operat ions Department 25 Technology Place Hingham, MA 02043 Tel: 1 -800-366-7778 Fax: 1 -800-583-6289 Policy History Date Action 7/2023 Reformatted Policy. 4/2023 Clarified not covering Organ Rejection. 7/2022 Renamed policy to be inclusive of IV and SubQ products. 12/2021 BCBSA National medical policy review. No changes to policy statements. New references added. 2/2021 Updated to add PANDAS & PANS in line with state mandate. 1/2021 Coding information clarified. 12/2020 BCBSA National medical policy review. No changes to policy statements. New references added. 10/2020 Clarified coding information 4/2020 Updated to add Asceniv to the policy. 7 11/2019 Updated to add Xembify to the policy. 7/2019 Updated to add Cutaquig to the policy. 1/2019 Clarified coding information . 8/2018 Updated to include Association coverage statement for Neuromyelitis Optica & Blistering disease. 10/2017 Clarified coding information plus u pdated to change Walgreens Specialty Name. 7/2017 Updated to add AllCare to Pharmacy Specialty list. 6/2017 Updated address for Pharmacy Operations. 1/2016 Updated to add new HCPCS code J1575. 10/2015 Updated to included revised language for Pharmacy only medications. 7/2015 Update to include Retail billing. 6/2015 Updated to include Bivigam, Cytogam, Gammaplex, to align . 2/2015 Updated to include a couple HCPCS codes and one ICD code. 7/2014 Updated Coding section with ICD10 procedure and diagnosis codes, effective 10/2015. 1/2014 Updated ExpressPAth Language. 1/2013 Updated 1/2013 \u00ae-C. 11/2011 -4/2012 Medical policy ICD 10 remediation: Formatting, editing and coding updates. No changes to policy statements. 1/2012 Reviewed - Medical Policy Group - Neurology and Neurosurgery. No changes to policy statements. 11/2011 Reviewed - Medical Policy Group - Plastic Surgery and Dermatology. No changes to policy statements. 10/2011 Reviewed - Medical Policy Group - Gastroenterology, Nutrition and Organ Transplantation. No changes to policy statements. 9/2011 Reviewed - Medical Policy Group - Urology and Obstetrics/Gynecology. No changes to policy statements. 1/2011 Reviewed - Medical Policy Group - Neurology and Neurosurgery. No changes to policy statements. 12/2010 Reviewed - Medical Policy Group - Plastic Surgery and Dermatology. No changes to policy statements. 11/2010 Reviewed - Medical Policy Group - Gastroenterology, Nutrition and Organ Transplantation. No changes to policy statements. 10/2010 Reviewed - Medical Policy Group - Urology and Obstetrics/G ynecology. No changes to policy statements. 9/2010 Reviewed - Medical Policy Group - Hematology and Oncology. No changes to policy statements. 1/2010 Reviewed - Medical Policy Group - Neurology and Neurosurgery. No changes to policy statements. 12/2009 Reviewed - Medical Policy Group - Plastic Surgery and Dermatology. No changes to policy statements. 11/2009 Reviewed - Medical Policy Group - Gastroenterology, Nutrition and Organ Transplantation. No changes to policy statements. 10/2009 Reviewed - Medical Policy Group - Urology and Obstetrics/Gynecology. No changes to policy statements. 9/2009 Reviewed - Medical Policy Group - Hematology and Oncology. No changes to policy statements. 10/2009 Updated to reflect UM requirements. 1/2009 Reviewed - Medical Policy Group - Neurology and Neurosurgery. No changes to policy statements. 12/2008 Reviewed - Medical Policy Group - Plastic Surgery and Dermatology. No changes to policy statements. 8 11/2008 Reviewed - Medical Policy Group - Gastroenterology, Nutrition and Organ Transplantation. No changes to policy statements. 10/2008 Reviewed - Medical Policy Group - Urology and Obstetrics/Gynecology. No changes to policy statements. 10/2008 Reviewed - Medical Policy Group - Hematology and Oncology. No changes to policy statements. 1/2008 Reviewed - Medical Policy Group - Neurology and Neurosurgery. No changes to policy statements. 9/2007 Reviewed - Medical Policy Group - Hematology and Onco logy. No changes to policy statements. 1/2007 Reviewed - Medical Policy Group - Neurology and Neurosurgery. No changes to policy statements. References 1. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Neurology. May 1991; 41(5): Hadden RDM, Bouche P, et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - First Revision. Eur J Neurol. 2010;17:356 -363. 23, 2021 3. Food and Drug Administration (FDA). Vaccines, Blood 4. Shehata N, Palda V, Bowen T, et al. The use of immunoglobulin therapy for patients with primary immune deficiency: an evidence -based practice guideline. Transfus Med Rev. Jan 201 0; 24 Suppl 1: S28-50. PMID 19962579 5. Ochs HD, Gupta S, Kiessling P, et al. Safety and efficacy of self -administered subcutaneous immunoglobulin in patients with primary Asensio O, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies --a prospective, multi -national for primary and secondary immunodeficiencies: an Aug al. Immunoglobulin prophylaxis in hematopoietic ste m cell transplantation: systematic -Blanchette S, Hutton B, et al. Clinical outcomes of polyvalent immunoglobulin use in solid organ transplant recipients: A systematic al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensi tized adult patients with end -stage renal disease: report of the NIH IG02 trial. al. Rituximab and intravenous immune globulin for desensitization during renal trans plantation. N Engl J Med. Jul 17 2008; 359(3): 12. Alachkar N, al. Infusion of high -dose intravenous immunoglobulin fails to lower the strength of human leukocyte antigen antibodies in highly sensitized patients. Transplantation. Jul 27 2012; 94(2): 165 -71. PMID 22735712 13. Kozlowski T, Andreoni K. Limitations of rituximab/IVIg desensitization protocol in kidney transplantation; is this better than a tincture of time?. Ann Transplant. Apr -Jun 2011; 16(2): 19 -25. PMID 21716181 9 14. Marfo K, Ling M, Bao Y, et al. Lack of effect in desensitization with intravenous immunoglobulin and rituximab in highly 15. Stegall JL, comp arison of plasmapheresis versus high -dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant. Feb 2006; 6(2): 346 -51. PMID 16426319 16. Mohan S, Tsapepas D, et al. Donor -specific an tibodies adversely affect kidney allograft outcomes. J Nephrol. Dec 2012; 23(12): 2061 -71. PMID 23160511 17. Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA -incompatible kidney recipients and survival. N Engl J Med. Jul 28 2011; 365(4): 318-26. PMID 21793744 18. Roberts DM, Jiang SH, Chadban SJ. The treatment of acute antibody -mediated rejection in kidney transplant recipients -a systematic review. Transplantation. Oct 27 2012; 94(8): 775 -83. M, Opelz G, et al. A randomized and prospective study comparing treatment with high -dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid -resistant rejection. Transplantation. Jan 15 2001; 71(1): 53 -8. PMID 11211195 20. Gale RP, Chapel HM, Bunch C, et al. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. N al. Randomized trial of intravenous immunoglobulin prophylaxis for patients , Chiurazzi low -dose intravenous immunoglobulins (IVIG) in chronic lymphocytic M, Gamm H, et al. Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimes. Br J Sep 1994; 88(1): 209 -12. PMID 7803248 Lea J, et al. Crossover study of immunoglobulin replacement therapy in patients with low -grade B -cell tumors. Blood. Feb 1989; 73(2): 366 -8. PMID 2492832 25. Raanani Paul M, et al. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: PMID 19330654 26. National Institute of Child Health and Human Developments Intravenous Immunoglobulin Study Group. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodefi ciency virus infection. N Engl J Med. Jul 11 1991; 325(2): 73 27. Ohlsson Intravenous immunoglobulin for preventing infection in preterm and/or low birth weight infants. Cochrane Database Syst 02 or proven infection in neonates. Syst Rev. Jan 29 2020; 1: CD001239. PMID 31995649 29. Brocklehurst P, Farrell B, King A, et al. Treatment of neonatal sepsis with intraveno us immune globulin. N Engl J Med. Sep 29 365(13): et al. Intravenous immunoglobulin in septic shock: review of the mechanisms of action and meta -analysis of the clinical effectiveness. Minerva Anestesiol. May 2016; 82(5): 559 -72. PMID 26474267 31. Ito S, Oyake T, Uchiyama T, et al. Successful treatment with cyclosporine and high -dose gamma immunoglobulin for persistent parvovirus B19 infection in a patient with refractory autoimmune hemolytic anemia . Int J 32. Koduri Kumapley R, Khokha ND, et Red cell aplasia caused by parvovirus B19 Chuhjo S, Matsuda T. Successful treatment of persistent erythroid aplasia caused by parvovirus B19 infection in a patient with common variable immunodeficiency with low -dose immunoglobulin. F, al. Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus b19 infection: a retrospective study of 10 patients and review of the literature. Clin Infect Dis. Apr 2013; 56(7): 968 -77. 35. N, J, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double -blind, placebo -controlled trial. Clin Dis. PMID 12884156 36. Linner A, Darenberg J, Sjolin J, e t al. Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study. Clin Sep 15 59(6): et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome --a comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis. MP, Mcgeer A, et a l. Successful management of severe group A streptococcal soft tissue infections using an aggressive medical regimen including intravenous polyspecific immunoglobulin together with a conservative surgical approach. Scand J Infect Dis. 2005; 37(3): 166 -72. P MID 15849047 39. Shah SS, Hall M, Srivastava R, et al. Intravenous immunoglobulin in children with streptococcal toxic shock syndrome. Nov 01 2009; 49(9): 1369 -76. PMID 19788359 40. Anderson D, Ali K, Blanchette V, et al. Guidelines on the use of intravenous immune globulin for hematologic conditions. Intravenous immunoglobulin or high -dose methylprednisolone, with or without oral prednisone, for ad ults with untreated severe autoimmune thrombocytopenic 42. von dem Borne AE, Vos JJ, Pegels JG, et al. High dose intravenous methylprednisolone or high dose intraveno us gammaglobulin for autoimmune thrombocytopenia. Br Med J (Clin Res Ed). Jan 23 1988; 296(6617): 249 -50. PMID 2449258 43. Jacobs P, Wood L. The comparison of gammaglobulin to steroids in treating adult immune thrombocytopenia. An interim analysis. Blut. Jul 1 989; 59(1): 92 -5. PMID 2752179 RA, Doorn Intravenous immunoglobulin for Guillain -Barre trial of intravenous immunoglobulin, and combined treatments in Guillain -Barre syndrome. Plasma Exchange/Sandoglobulin Guillain -Barre Syndrome Trial Group. Lancet. Jan 25 1997; 349(9047): 225 -30. PMID 9014908 46. Overell JR, Hsieh ST, Odaka M, et al. Treatment for Fisher syndrome, Bickerstaff's b rainstem encephalitis and related disorders. et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in se Syst Intravenous immunoglobulin as adjuvant therapy for 23440811 49. DR, Intravenous immunoglobulin for ANCA -associated syste KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. Dec 1994; 36(6): 838 52. Hughes R, Ben sa S, Willison H, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone for inflammatory Brand A , et al. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Psychiatry. Jan 1993; 56(1): 36 55. Hahn CF, Zochodne D, e t al. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double -blind, placebo -controlled, cross PMID 8813271 56. Thompson N, Choudhary P, Hughes RA, et al. A novel tr ial design to study the effect of intravenous immunoglobulin in chronic inflammatory RA, al. Intravenous immune globulin (10% caprylate -chromatography for (ICE van Geloven N, et al. Subcutaneous (PATH): a randomised, double -blind, controlled, Lancet Subcutaneous immunoglobulin as fir st-line therapy in treatment -naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial 412 -418. PMID 28000311 IN, Haan R, et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti -GM1 antib odies: multifocal motor neuropathy: a 65. Van den Berg LH, Kerkhoff H, Oey PL, et al. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry. Sep 1995; 59(3): 248 Bain PG, Motomura Newsom -Davis J, et al. Effects of intravenous immunoglobulin on muscle weakness and calcium -channel autoantibodies Vidal A, et al. Long -term follow -up of Lambert -Eaton syndrome treated with intravenous immunoglobulin. Muscle Nerve. Jun 674 68. Rich MM, Teener SJ. Treatment of Lambert -Eaton syndrome with 69. Takano H, Koike R, al. Effect of intravenous immunoglobulin in Lambert -Eaton myasthenic syndrome with small -cell cancer: correlation with the titer of anti -voltage -gated calcium channel antibody. Muscle Nerve. 1994; 17(9): 3-5. PMID 8065398 70. Bird SJ. K, et al. Role of intravenous immunoglobu lin in the treatment of acute relapses of neuromyelitis optica: experience in immunoglobulin in patients with myasthenia g ravis: a randomized controlled Neurology. Mar 13 17353471 75. Barth D, Nabavi Nouri M, Ng E, et al. Comparison of IVIg and PLEX in patients with al. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin : a Clair B, et al. Clinical trial of plasma exchange and high -dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinic GP, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neur ology and the MS Council for Clinical Practice Guidelines. Neurology. Jan 22 2002; 58(2): 169 - 78. PMID Gurcan HM, therapy in autoimmune mucocutaneous blistering diseases: a review of the evidence for it s efficacy and safety. Am J Clin Dermatol. Hashimoto T, al. A randomized double -blind trial of intravenous randomized double -blind of Chen YT, et al. Intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: Aronoff SC. Intravenous immunoglobulin in the treatment of Stevens - Johnson syndrome and toxic epidermal necrolysis: a meta -analysis with meta Jan 2015; 54(1): 108 -15. PMID 24697283 84. Shu XM, Tian XL, et al. Intravenous immunoglobulin therapy in adult patients with polymyositis/dermatomyos itis: literature review. controlled trial of high -dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. Dec 0 1993; 329(27): -2000. PMID 8247075 86. Miyasaka N, Koike T, et al. Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double - blind placebo Treatment of inclusion -body myositis with IVIg: a double - blind, Walter H, Toepfer M, et al. High -dose immunoglobulin therapy in sporadic inclusion body myositis: a double -blind, placebo -controlled study. J Koffman controlled study of intrav enous immunoglobulin combined with prednisone in the treatment 13 therapeutic armamentarium of systemic lupus erythematosus: a systematic re view Orange al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Sellebjerg F, et al. A double -blind, randomized trial of IV immunoglobulin treatment in acute et A randomized of intravenous immunoglobulin for the ent of Crohn's 2012; 12(2): 275 -80. PMID 22579561 13 96. Rajagopala S, Singh N. Diagnosing and treating hemophagocytic lymphohistiocytosis in the tropics: systematic review from A, JP, et al. Successful treatment of cytomegalovirus -associated hemophagocytic by al . Hemophagocytic syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma; successful treatment with high -dose intravenous immunoglobulin. 16518425 99. Arlet Marin ho A, al. Reactive haemophagocytic syndrome in adult -onset Still's disease: a report of six patients and a review of the literature. Ann Rheum Dis. Dec 2006; 65(12): 1596 G, Newland AC, et al. Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: results in 73 patients. Am response intravenous immunoglobulin in haemolytic Espinosa R, et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death an d prognostic factors in a series of 250 patients. Arthritis Low -Dose Intravenous Immunoglobulin to JG, et al. Antepartum treatment without early cordocentesis for standard -risk alloimmune al. Parallel randomized risk -based therapy for fetal thrombocytopenia with intravenous gamma -globulin: a randomized trial of the addition of low -dose steroid to intravenous gamma Immunotherapy for recurrent miscarriage. P, et al. The Effects of Intravenous Immunoglobulins in Women with Recurrent Miscarriages: A Systematic Review of Randomised Trials with Meta -Analyses and Trial Sequential Analyses One. 2015; 10(10): PMID 26517123 110. Wang SW, et al. The effect of intravenous immunoglobulin passive immunotherap y on unexplained recurrent 111. Christiansen OB, Pedersen B, Rosgaard A, et al. A randomized, double -blind, placebo -controlled trial of intravenous immunoglobul in in the prevention of recurrent miscarriage: evidence for a therapeutic effect in women with secondary recurrent miscarriage. Hum Reprod. Mar 2002; et al. A multicenter, placebo -controlled pi lot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. Am J Obstet Gynecol. Jan A, Palfi M, et al. Prevention of recur rent spontaneous abortion by intravenous immunoglobulin: a double Swedo CA, et al. Randomized, Controlled Trial of Intravenous Immunoglobulin for Ped iatric Autoimmune Neuropsychiatric Disorders Associated With 14 Streptococcal Infections. J Am Acad Adolesc plasma exchange and intravenous immunoglobulin for obsessive -compulsive disorder and tic disorders in Lancet. Oct 02 1999; 354(9185): 1153 -8. PMID 10513708 116. Gupta S, Aggarwal S, Heads C. Dysregulated immune system in children with autism: beneficial effects of intravenous immun e globulin on autistic characteristics. J Autism Dev Disord. Aug 1996; 26(4): 439 -52. PMID 8863094 117. Plioplys AV. Intravenous immunoglobulin treatment of children 13(2): 79 -82. L, S chmeidler J, et al. Brief report: a pilot open clinical trial of intravenous immunoglobulin in childhood autism. J Autism Dev Disord. Apr 29(2): 157 -60. PMID 10382136 119. Low -Dose Intravenous Immunoglobulin Treatme nt for Long - Standing Complex Regional Pain Syndrome: A Randomized Trial. Ann Intern Med. K, et al. Intravenous immunoglobulin treatment of the complex regional pain syndrome: a rand omized trial. Ann Intern Med. Feb 02 2010; 152(3): PMID 20124231 121. Relkin NR, Thomas RG, Rissman RA, et al. A phase 3 trial of IV immunoglobulin for Alzheimer disease. Neurology. Parise C, et al. IVIG treatment of mild cognitive impairment due to Alzheimer's disease: a randomised double -blinded exploratory study of the effect on brain atrophy, cognition and conversion to dementia. J Neurol Bartenstein et al. immunoglobulin for treatment of mild -to- moderate Alzheimer's disease: a phase 2, randomised, double -blind, placebo -controlled, L, Swan A, et al. A randomised controlled trial of intravenous immunoglobulin in et al. Intravenous immunoglobulin is ineffective in the treatment of patients with chronic fatigue syndrome. Am J Med. Jul 1997; 103(1): 38 -43. PMID 9236484 127. B, et al. Intravenous immunoglobulin for presumed viral myocarditis in children and adults. Syst Rev. May 2015; et al. Intravenous immunoglobulin for presumed viral myocarditis in children and adults. Syst Rev. Aug RC, et al. Controlled trial of intravenous immune globulin in recent -onset 130. Kishimoto C, Shioji K, Hashimoto T, et al. Therapy with immunoglobulin in patients wi th acute myocarditis and cardiomyopathy: analysis PMID 23702697 131. El-Saiedi SA. Randomized controlled trial on the use of intravenous immune globulin in acute pediatric myocarditis. J Clin 2021 132. Huang X, Sun Y, Su G, et al. Intravenous Immunoglobulin Therapy for Acute Myoca rditis in Children and Adults. Int Heart J. 60(2): 359 JG, et al. Intravenous immunoglobulins in children with new al. Intravenous human immunoglobulins for refractory recurrent pericarditis: a systematic review of all published cases. J Cardiovasc Med (Hagerstown). M, al. High -dose intravenous immune globulin for stiff -person syndrome. N MB, Hjortrup PB, Hansen MB, et al. Immunoglobulin G for patients with necrotising soft tissue infection ( INSTINCT): a randomised, blinded, placebo 2017; 28421246 140. Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: A review of evidence. J ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. N, VA, Meyer RM, et al. The use of immunoglobulin therapy for patients undergoing solid organ transplantation: an evidence -based practice guideline. Transfus Med Rev. Jan 2010; 24 Suppl 1: S7 -S27. 19962580 143. National Comprehensive Cancer Network (NCCN). Practice Guidelines Version 4.2021. https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf. Accessed August 31, 2021 144. Centers for Disease Control (CDC). Guidelines for t he prevention and treatment of opportunistic infections among HIV -exposed and HIV -infected children: bacterial infections. 2013; https://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf. Accessed August 31, 2021 145. Polin RA, Committee o n Fetus Newborn. Management of neonates with suspected or proven early - onset bacterial sepsis. Pediatrics. https://pediatrics.aappublications.org/content/pediatrics/142/6/e20182894.full.pdf. Accessed August 31, 2021 146. Patwa HS, Chaudhry V, Katzberg H, et al. Evidence -based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. Mar 27 2012; 78(13): 1009 -15. PMID 2245426 8 147. Saguil A, Fargo M, Grogan S. Diagnosis and management of kawasaki disease. Am Fam Physician. Mar 15 2015; 91(6): McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, Treatment, and Long -Term Management of Kawasaki Disease: A Sci entific Statement for Health Professionals From the American Heart Association. Circulation. Apr 25 2017; 135(17): e927 Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force - second revision. J Peripher Nerv Syst. 2021;1 -27. https://onlinelibrary.wiley.com/doi/10.1111/jns.12455. Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis 24272588 GI, Benatar M, et al. Inte rnational consensus guidance for management of myasthenia gravis: Executive Neurology. Jul 26 2016; 87(4): 419 -25. PMID 27358333 152. Ahmed AR, Dahl MV. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune 16 153. Creamer D, Walsh SA, Dziewulski P, et al. U.K. guidelines for the management of Stevens -Johnson syndrome/toxic epidermal necrolysis in adults 2016. Biswas S, et al. British Association of Dermatologists' guidelines for the management of Stevens -Johnson syndrome/toxic epidermal necrolysis in children and young D ermatol. 2019;181:37 -54. doi: 10.1111/bjd.17841. -Pinto I, Cervera R, et al. Catastrophic antiphospholipid syndrome: of Obstetricians and Gynecologists. The Investigation and Treatment of Couples with Recurrent Firsttrimester and Second -trimester Miscarriage. Royal Colleg of Obstetricians and Gynecologists Green -Top Guidelines No. 17. https://www.rcog.org.uk/globalassets/documents/guidelines/gtg_17.pdf. September 1, 2021 157. Feasby T, Banwell B, Benstead T, et al. Guidelines on the use of intravenous immune globulin for neurologic conditions. -Smith M, et al. Practice parameter for the assessment and treatment of children and adolescents with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry. Feb 2014; 53(2): 237 -57. PMID 24472258 159. National Institute for Health and Care Excellence (NICE). Chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy): diagnosis and management [CG53]. 2007; https://www.nice.org.uk/guidance/cg53. Accessed September 1, 2021 160. Writing Committee Members, Yancy CW, Jessup M, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. https://www.jacc.org/doi/full/10.1016/j.jacc.2013.05.019?_ga=2.248107975.1773510622.163053172 9-1275499959.1630531729 Accessed September 1, 2021 161. Centers for Medicare & Medicaid Services (CMS). National Coverage Determination for intravenous immune globulin for the treatment of Revised 9/95 based on TEC (Technology Evaluation Center) 6/95 assessment of medical literature from 1991 to 1995 addressing IVIg for SLE -related cytopenia, vasculitis, pericarditis, and pleural effusions patients who were not controlled by immunosuppressives or cytotoxic agents. 2. Revised 9/95 to include the 2/95 TEC evaluation of medical literature from 1991 -4/95 assessing IVIg to improve the functional status of patients with inclusion body myositis who have not responded to prednisone or other immunosuppressives. 3. Revised 10/95 based on 1994 TEC evaluation of medical literature from 1991 -1994 assessing IVIG to stop progression of muscle weakness or to decrease frequency or severity of relapses in MS.. 4. Revised 10/95 based on a 1994 TEC evaluation of medical literature from 1991 -1994 assessing IVIg to impro ve functional capacity or to reduce pain in patients with RA refractory to NSAIDS and either cytotoxic or disease -modifying antirheumatic drugs. 5. Revised 10/95 based on a 1994 TEC evaluation of medical literature from 1991 -1994 assessing IVIG to improve neurologic function in CIDP, either as first -line therapy, or for acute exacerbations in patients refractory or intolerant of prednisone or azathioprine. 6. Revised 10/95 based on a 1994 TEC evaluation of medical literature assessing IVIG to reduce fetal loss in women with recurrent fetal loss (sequence of 3 or more miscarriages), with or without antiphospholipid antibodies. 7. Revised 3/96 to include CMS (Centers for Medicare and Medicaid services) regulations published in the February/March 1996 issue of th e Medicare Health Resources. 8. Revised 2/97 to include CMS (Centers for Medicare and Medicaid services) regulations published in the February/March 1997 issue of the Medicare Health Resources. 9. Revised 9/97 to include CMS regulations (Centers for Medicare and Medicaid services) published in the June/July 1997 Medicare B Health Resources. 17 10. Added based on recommendations made by the Massachusetts Neurological Society. 11. Based on the July 1998 TEC (Technology Evaluation Center) analysis of the literature on IVIg for MS. Health outcomes considered by TEC included prevention of disease progress and disability, improving baseline neuro disability, and reducing acute relapse. Also see the July/August 1997 ACP Journal Club commentary: http://www.acponline.org/jou rnals/acpjc/julaug97 Regarding the article: Fazekas F et al., Austrian Immunoglobulin in Multiple Sclerosis Study Group. Randomized placebo -controlled trial of monthly intravenous immunoglobulin therapy in relapsing - remitting multiple sclerosis. Lancet. 19 97 Mar 1;349:589 -93. 12. FDA -approved uses as of July, 1998 . 13. Off -label use in the treatment of AIDS and HIV as required by law. 14. Label use based on National Blue Cross Blue Shield policy 8.01.05, issued 12/15/98 . 15. Off -label use based on Nati onal Blue Cross Blue Shield policy 8.01.05, issued 12/15/98 . 16. Investigational use based on National Blue Cross Blue Shield policy 8.01.05, issued 12/15/98 . 17. Based on recommendations from Walt Kagan, MD, Massachusetts Society of Clinical Oncologists. 18. Based upon a September 1999 Medicare B HealthResource Newsletter. 19. Medicare policy is developed separately from BCBSMA policy. While BCBSMA policy is based upon scientific evidence, Medicare policy incorporates scientific evidence wi th local expert opinion, and governmental regulations from CMS (Centers for Medicare and Medicaid Services) and the U.S Congress. While BCBSMA and Medicare policies may differ, our Medicare HMO Blue and Medicare PPO Blue members must be offered the same s ervices as Medicare offers. In many instances, BCBSMA policies offer more benefits than does Medicare policy. 20. Based on recommendations from David Weinberg, MD, Massachusetts Neurologic Association, 1/2000 MPG Neurology meeting. 21. Medical Policy Gr oup, August 2000. 22. Previous criteria summarized in the current form: vital capacity less than 1L; dysphagia associated with aspiration; inability to ambulate 100 feet without assistance. 23. Medical Policy Group, January 2000. 24. Idiopathic Thrombocytopenic Purpur a: A Practice Guideline Developed by Explicit Methods for the American Society of Hematology 25. See the 1998 ASRM (American Society of Reproductive Medicine) Practice Committee Report on Intravenous Immunoglobulin and Spontaneous Pregnancy Loss. 26. Based on the June 2002 Medicare B Resource Newsletter. See also the CMS /Medicare websites at www.cms.gov and www medicare.gov. 27. Based upon the 2002 Blue Cross Blue Shield Associ ation policy 8.01.05. IVIG for myasthenic crisis is considered medically necessary. Myasthenic crisis is an off -label indication. 28. Based upon the 2002 Blue Cross Blue Shield Association National policy 8.01.05. 29. Based upon the 2004 Blue Cros s Blue Shield Association policy 2.01.01. 30. Based upon the 2004 Blue Cross Blue Shield Association National policy 8.01.05. 31. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blister ing diseases. Arch Dermatol.2003;139:1051 -1059. 32. Based upon the 2004 BCBSA National Policy 8.01.05. Bone marrow transplant patients (for prevention of infection or GVH prevention.) Cordonnier C, Chevret S, Legrand M et al. Should immunoglobulin therapy be used in allogeneic stem -cell transplantation? A randomized, double -blind, dose effect, placebo -controlled multicenter trial. Ann Intern Med 2003;139(1):8 -18. 33. Based upon the 2004 BCBSA National Policy 8.01.05. Recurrent Spontanous Abortion. 34. Based on Blue Cross Blue Shield National policy 8.01.05 Intravenous Immune Globulin Therapy issued 4/06. To request prior authorization using the Massachusetts Sta ndard Form for Medication Prior Authorization Requests (eForm), click the link below: http://www.bluecrossma .org/medical -policies/sites/g/files/csphws2091/files/acquiadam - assets /023%20E%20Form%20medication%2 prior%20auth%20instruction%20prn.pdf 18 Home Infusion Therapy Prior Authorization Form Please complete and fax with the physician's prescription to: (888) 641 -5355. If the patient is a BCBSMA employee, please fax the form to: (617) 246-4013. receipt/transmission per HIPAA requirements? (circle one) Yes No Place of Service Home SNF MD office other (specify)_____________________ Primary Therapy Primary drug name: Dose: Frequency: Route drug name: Approximate ____/____/____ to ____/____/____ Dose: Frequency Route of pump: Y N If this is a \"drug only\" authorization request, indicate other services the nursing agency is providing: ______________________________________________________________________________________ Nursing provided by: ________________________________ Contact: _________________________ Phone: ______________ Fax: ___________________ Request for Day Coverage : Date of occurrence: ___________ request dates:___________________ Occurrence type: Hospitalization Death Change of Therapy Physician signature:_______________________________________________ Date:____________________ OR Copy of prescription REQUIRED with this request "}